会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • グリコペプチド抗生物質ダイマー誘導体
    • 糖蛋白抗生物二聚体衍生物
    • WO2006057288A1
    • 2006-06-01
    • PCT/JP2005/021564
    • 2005-11-24
    • 国立大学法人名古屋大学塩野義製薬株式会社有本 博一路 軍山野 佳則吉田 修
    • 有本 博一路 軍山野 佳則吉田 修
    • C07K7/00A61K38/00A61P31/04
    • C07K9/006
    • Novel glycopeptide antibiotic dimer derivatives. The derivatives are represented by the formula (X) [wherein A 1 and A 2 each independently represents the formula (aglycon moiety of glycopeptide antibiotic derivative)-(Sac-NH)-X 1 -Ar-X 2 -Y-X 3 - (wherein the (aglycon moiety of glycopeptide antibiotic) is the part obtained by removing the sugar moiety from a known glycopeptide antibiotic; (Sac-NH) part is an amino sugar or a sugar chain part containing an amino sugar; X 1 , X 2 , and X 3 each independently represents 1) a single bond, 2) a heteroatom (group) selected from the group consisting of -N=, =N-, -NR 1 -, -O-, -S-, etc., or 3) optionally substituted alkylene or alkenylene; Ar represents a carbocycle, heterocycle, single bond, etc.; and Y represents -NR 2 CO-, -CONR 2 -, a single bond, etc.)]. These derivatives have antibacterial activity against vancomycin-resistant bacteria.
    • 新型糖肽抗生素二聚体衍生物。 衍生物由式(X)表示[其中A 1和A 2各自独立地表示式(糖肽抗生素衍生物的糖苷配基部分) - (Sac-NH) - 其中(糖肽抗生素的糖苷配基部分)是通过除去 来自已知糖肽抗生素的糖部分;(Sac-NH)部分是含有氨基糖的氨基糖或糖链部分; X 1,X 2和X 2 各自独立地表示1)单键,2)选自-N =,= N,-NR 1 - 的杂原子(基团), -O - , - S-等,或3)任选取代的亚烷基或亚烯基; Ar表示碳环,杂环,单键等; 和Y表示-NR 2 CO-,-CONR 2 - ,单键等)]。 这些衍生物对万古霉素抗性细菌具有抗菌活性。
    • 3. 发明申请
    • グリコペプチド抗生物質誘導体
    • 谷氨酸抗生素衍生物
    • WO2007138999A1
    • 2007-12-06
    • PCT/JP2007/060673
    • 2007-05-25
    • 塩野義製薬株式会社西谷 康宏吉田 修岩耒 努加藤 一生
    • 西谷 康宏吉田 修岩耒 努加藤 一生
    • C07K9/00A61K38/00A61P31/04C07K7/06C07K14/36
    • C07K9/008A61K38/00A61K38/04
    • It is intended to provide a novel glycopeptide antibiotic derivative. A compound represented by the formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof. In the formula (I), R A represents -X 1 -Ar 1 -X 2 -Y-X 3 -Ar 2 (X 1 , X 2 , X 3 represent a single bond, a heteroatom group selected from -N=, =N-, -NR 1 - (R 1 represents H or lower alkyl), -O-, -S-, -SO-, and -SO 2 - or a linking group thereof, or alkylene or alkenylene which may be interrupted or substituted by one or more of such heteroatom groups; Y represents -NR 2 CO-, -CONR 2 - (R 2 represents H or lower alkyl) or a group represented by the formula (II) (R 3 represents alkylene); Ar 1 and Ar 2 represent a carbocyclic group or heterocyclic group which may be substituted and have an unsaturated bond; R B represents -NHNR X R Y or -NR Z OR W (R X represents hydrogen or lower alkyl, R Y represents hydrogen or lower alkyl which may be substituted, C(=NH)NH 2 , CSNH 2 , COCONH 2 , CN, a heterocyclic group which may be substituted or carbamoyl which may be substituted; R Z represents hydrogen or lower alkyl; R W represents hydrogen, lower alkyl which may be substituted, lower alkenyl which may be substituted, a heterocyclic group which may be substituted, heterocyclic carbonyl which may be substituted or carbamoyl which may be substituted); R C represents hydrogen or alkyl which may be substituted (the alkyl may be interrupted by a heteroatom group selected from N=, =N-, -NR 1 - (R 1 represents H or lower alkyl), -O-, -S-, -SO-, and -SO 2 -); R represents alkyl which may be substituted.
    • 旨在提供一种新型的糖肽抗生素衍生物。 由式(I)表示的化合物,其药学上可接受的盐或其溶剂合物。 在式(I)中,R A表示-X 1,-S 2,...,X 2, (X 1,X 2,X 3,X 3)代表单一的 键,选自-N =,= N-,-NR 1 - 的杂原子基(R 1表示H或低级烷基), - O - , - S- ,-SO-和-SO 2 - 或其连接基团,或可以被一个或多个这样的杂原子基团中断或取代的亚烷基或亚烯基; Y表示-NR2 (R 2表示H或低级烷基)或由式(II)表示的基团(R 3) 代表亚烷基); Ar 1和Ar 2代表可以被取代并具有不饱和键的碳环基或杂环基; R B, / SUP>表示-NHNR X R Y或-NR Z或/或W(R X) / SUP>表示氢或低级烷基,R Y表示氢或可被取代的低级烷基, C(= NH)NH 2,CSNH 2,COCONH 2,CN,可被取代的杂环基或可被取代的氨基甲酰基 ; R Z表示氢或低级烷基; R W表示氢,可被取代的低级烷基,可被取代的低级链烯基,可被取代的杂环基,可被取代的杂环羰基或可被取代的氨基甲酰基; (R')可以被取代(烷基可以被选自N =,N-,-NR 1 - O,-S - , - SO-和-SO 2 - )表示H或低级烷基,-O - , - S - , - SO-和-SO 2 - 。 R代表可被取代的烷基。